Theravance Biopharma TBPH Short- and long-term operating lease liabilities
Short- and long-term operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's short- and long-term operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's short- and long-term operating lease liabilities?
- Theravance Biopharma (TBPH) reported short- and long-term operating lease liabilities of -$2.2M in Q1 2026.
- How has Theravance Biopharma's short- and long-term operating lease liabilities changed year-over-year?
- Theravance Biopharma's short- and long-term operating lease liabilities decreased by 32.2% year-over-year, from -$1.66M to -$2.2M.
- What is the long-term trend for Theravance Biopharma's short- and long-term operating lease liabilities?
- Over 3 years (2021 to 2025), Theravance Biopharma's short- and long-term operating lease liabilities has grown at a 27.1% compound annual growth rate (CAGR), from -$3.47M to -$7.12M.